Respiration

RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury

Retrieved on: 
Mercoledì, Maggio 29, 2024
DOD, Patient, Bangladesh Technical Education Board, Catheter, Doctor of Philosophy, Ampakine, Human, SCI, Risk, RespireRx, Pleasure, University, News, IND, Trial of the century, Government, Safety, Publication, Principal investigator, Locomotion, Spinal cord injury, Assistant, Animal, Research, CSO, Neurogenic bladder dysfunction, Incidence, Acquisition, Bourbeau, Health Affairs, Rehabilitation, Respiration, Death, Quality of life, Pharmaceutical industry

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Assistant Secretary of Defense for Health Affairs or the Department of Defense.

Key Points: 
  • Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Assistant Secretary of Defense for Health Affairs or the Department of Defense.
  • As the Principal Investigator, Dr. Sandhu will conduct the clinical trials at Shirley Ryan AbilityLab.
  • Restoration of bladder function is ranked as one of the highest priorities by individuals with SCI (Bourbeau et al., Spinal Cord 58:1216–1226; 2020).
  • With this new non-dilutive funding, we have begun planning to conduct translational, Phase 2 studies in SCI patients late this year.

Spinogenix Announces FDA Clearance of IND Application for SPG302, a Novel Therapy for the Treatment of ALS

Retrieved on: 
Mercoledì, Maggio 29, 2024
ODD, Patient, Pharmacokinetics, Massachusetts General Hospital, Plasma, Investigational New Drug, Hope, Food, Hospital, FDA, Doctor of Philosophy, IND, Disease, Safety, SAN, ALS, Speech, Harvard Medical School, Respiration, Synapse, Therapy, NIH, Pharmaceutical industry

The trial will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of SPG302 dosed as a once-a-day pill in ALS patients.

Key Points: 
  • The trial will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of SPG302 dosed as a once-a-day pill in ALS patients.
  • “Having completed the Phase 1 safety study in healthy subjects in Australia, we are thrilled to have gained FDA acceptance of our U.S. IND for SPG302 in ALS,” said Stella Sarraf, Ph.D., Spinogenix Chief Executive Officer and Founder.
  • “SPG302’s unique approach to regenerate synapses offers a fundamentally different treatment modality, focusing on synapse loss which is central to ALS.
  • Current treatments have not sufficiently met the needs of ALS patients, as slowing disease progression alone is not enough.

Animal Alerts powered by PetPace™ Turns Pet Health Data into Earthquake Warnings

Retrieved on: 
Lunedì, Maggio 20, 2024
Natural Disasters, Other Communications, Environment, Communications, Public Safety, IOT (Internet of Things), Other Technology, Mobile, Wireless, Public Policy, Government, Software, Other Science, Other Retail, Research, Data Management, Consumer Electronics, Wearables, Mobile Technology, Technology, Retail, Women, Science, Veterinary, Pets, Health, Men, Artificial Intelligence, Consumer, Human, Fire blanket, Risk, Algorithm, Pacific Ocean, Pulse, AI, Animal, Earthquake, London South Bank University, Pet, Dog, Respiration, Volunteering, Multimedia, Temperature, Radio

Animal Alerts is a project to develop the first earthquake warning system powered by PetPace, the industry leader in animal health monitoring.

Key Points: 
  • Animal Alerts is a project to develop the first earthquake warning system powered by PetPace, the industry leader in animal health monitoring.
  • View the full release here: https://www.businesswire.com/news/home/20240520194540/en/
    PetPace and Animal Alerts turn pet health data into early warning of earthquakes in Peru study.
  • Designed to ensure comfort for pets, the PetPace smart collar collects vital health data through its electrode-free, non-invasive sensors.
  • For effective earthquake warning, Animal Alerts has secured media partnerships through Mediaplus Group and Reset Media for the broadcasting of alerts through geo-targeted messages on digital billboards, web, mobile, and radio.

Yeast Market, Size, Global Forecast 2024-2030: Nutrition Demands Fuels Expansion into Diverse Sectors, Including Biofuels and Pharmaceuticals - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Maggio 9, 2024
Food, Beverage, Retail, Snack, Enzyme, Food quality, Wine, Beer, Respiration, Plasma protein binding, Vitamin, Transport, Vaccine, Biofuel, Automation, Food industry, Incidence, Biotechnology, Bread

Global demand for yeast is surging, driven by the need for fresh bread, pastries, and baked items in bakeries and houses internationally.

Key Points: 
  • Global demand for yeast is surging, driven by the need for fresh bread, pastries, and baked items in bakeries and houses internationally.
  • The comfort trend boosts the popularity of ready-to-bake products with yeast, providing an easy way to experience freshly baked items.
  • Yeast, identified for its dietary richness in vitamin B, protein, and fiber, finds utility in diverse sectors.
  • The country's affinity for diverse cuisines, from traditional bread to modern fermented products, amplifies yeast utilization.

'Plug and Play Topeka' Selects 26 Startups for Its Animal Health, Ag-Tech Accelerator Program

Retrieved on: 
Mercoledì, Aprile 10, 2024
Laboratory, AI, HR, Climate, Innovation, Poultry, Respiration, Parent, Farmer, Livestock, Farm, Soil, Hill, Table, Robotics, Dog, Oaken, Microplastics, Health, Cargill, Carbon, Automation, Agriculture, Genomics, Internet of things, Heart rate, Cat, Disease, Food, Economic development, Child, AG, Plug, Growth

TOPEKA, Kan., April 10, 2024 /PRNewswire-PRWeb/ -- In collaboration with GO Topeka, the economic development group for Kansas' capital city, Plug and Play Topeka, a global innovation platform that creates industry-specific accelerator programs, announced it has selected 15 animal health startups and 11 ag-tech startups for the spring 2024 cohort. These early-to-mid-stage startups hail from more than 10 countries, including the U.S., Norway, Sweden, Brazil, Germany, Spain, Italy, and the U.K., among others.

Key Points: 
  • Entrepreneurs representing these startups will now participate in a three-month-long accelerator program to connect them with resources and help their businesses get off the ground.
  • The 26 startups selected for the program are:
    Agrigator is helping agribusinesses address challenges from climate and operational uncertainties for sustainable growth through AI.
  • Since its start in the spring of 2021, 78 startups have graduated from the Plug and Play Topeka accelerator program.
  • Each year, the program will develop two accelerator groups, each comprising 10-12 animal health and ag-tech startups.

RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury

Retrieved on: 
Mercoledì, Marzo 20, 2024
OTC Markets Group, Neurogenic bladder dysfunction, Death, Ampakine, DOI, Tetraplegia, Rat, Incidence, Bourbeau, Risk, Bruise, Patient, Research, University, Bladder cancer, Quality of life, Pleasure, EMG, Alom, Catheter, AMPA, Injury, Interim, CSO, Bangladesh Technical Education Board, Urinary tract infection, Respiration, Animal, Kidney, SCI, Rana, RespireRx

Restoration of bladder function is ranked as one of the highest priorities by individuals with SCI (Bourbeau et al., Spinal Cord 58:1216–1226; 2020).

Key Points: 
  • Restoration of bladder function is ranked as one of the highest priorities by individuals with SCI (Bourbeau et al., Spinal Cord 58:1216–1226; 2020).
  • Current treatment approaches usually require interventions such as catheterization for urinary voiding, which have their own set of risks and potentially significant set of complications.
  • The present paper, entitled “Acute ampakines increase voiding function and coordination in a rat model of SCI” (Rana, Alom et al.
  • We believe that this research has the potential to represent a novel, breakthrough in the treatment of SCI, which is badly needed.”

Global Respiratory Care Devices Market Report, 2023-2024 and 2030: Infrastructure Improvements Key to Growth, Innovations in AI to Transform the Market Landscape - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Marzo 11, 2024
Medical Devices, Hospitals, Health, Health Technology, Medical Supplies, Hospital, Sleep apnea, Prevalence, Pneumonia, Emphysema, Tuberculosis, Intelligence, Incidence, Ageing, Patient, Respiratory therapist, Tissue, Chronic obstructive pulmonary disease, Research, Record, Quality of life, Human, Respiratory disease, Asthma, World Health Organization, CDC, Oxygen, WHO, TB, RMT, COPD, Allergy, Respiration, USD, Agonal respiration, Personal protective equipment

The rising incidence of respiratory diseases, which includes chronic obstructive pulmonary ailment, allergies, and sleep apnea, drives demand for respiration care devices.

Key Points: 
  • The rising incidence of respiratory diseases, which includes chronic obstructive pulmonary ailment, allergies, and sleep apnea, drives demand for respiration care devices.
  • This drives the demand for respiratory care devices to maintain adequate respiration and ensure most advantageous respiratory characteristic.
  • As the number of humans identified with respiration illnesses will increase, the demand for respiratory care devices is predicted to grow.
  • The Global Respiratory care devices marketplace requires a dependable and efficient infrastructure for low-earning individuals or healthcare centers.

REMSleep Holdings Shareholder Update

Retrieved on: 
Lunedì, Marzo 4, 2024
ISO, Blood pressure, Incidence, Ageing, Heart, Woman, Inhalation, Atmosphere, International Organization (journal), Dementia, CPAP, OSA, Obstructive sleep apnea, Pressure, Obesity, FDA, OTC, Smoking, Arrhythmia, Sleep, Biocompatibility, Exhalation, CHF, Risk, International Organization for Standardization, Consultant, Type 2 diabetes, Frustration, Engineering, BMI, DSM-IV codes, Non-invasive ventilation, Type, National Council, Respiration, Medical device

CLEARWATER, FL, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - REMSleep Holdings, Inc. (OTC PINK: RMSL) gives an update on FDA process and REMSleep status.

Key Points: 
  • CLEARWATER, FL, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - REMSleep Holdings, Inc. (OTC PINK: RMSL) gives an update on FDA process and REMSleep status.
  • We have had numerous inquiries asking for REMSleep regulatory status update.
  • REMSleep consultants are confident we will receive our 510(K) and we will never give up until we are successful.
  • REMSleep has addressed this problem by developing a novel CPAP nasal pillow interface that has been engineered to reduce pressure and enable better airflow.

Prilenia Announces Clinical Data in Support of its Plans to Initiate Global Phase 3 Study in ALS

Retrieved on: 
Venerdì, Gennaio 19, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ACT, Speech, Family, Dysarthria, Patient, Therapy, Spinal cord, HD, Drinking, ALS, Person, DSM-IV codes, Harvard Medical School, Friends, Respiration, Survival, Communication, Kaplan–Meier estimator, Quality of life, Cox, Eating, Safety, Disease, Caregiver, NIH, Hospital, Periodic breathing, Neurology, Master of Science, Massachusetts General Hospital, Bangladesh Technical Education Board, Pharmaceutical industry

The S1R is highly expressed in the brainstem and spinal cord, areas implicated in ALS and important for bulbar function and speech.

Key Points: 
  • The S1R is highly expressed in the brainstem and spinal cord, areas implicated in ALS and important for bulbar function and speech.
  • “We believe it is important for Prilenia to advance our clinical program in ALS, and we are actively planning a single, global, pivotal Phase 3 clinical trial.
  • Additional analyses from the same Phase 2 study of participants with definite or probable ALS who were also early and fast progressors were conducted.
  • Preliminary topline results in the full analysis set of this Phase 2 study were previously announced.

StePacPPC's New Sustainable Packaging Boosts Exotic Mushroom Longevity

Retrieved on: 
Mercoledì, Gennaio 24, 2024
Food safety, Overalls, Farmer, Weight loss, Respiration, Dehydration, Ward, Decomposition, Xtend, MAP, Restaurant, Marketing, Appetite, Ageing, Food preservation

TEFEN, Israel, Jan. 24, 2024 /PRNewswire/ -- Fresh produce packaging pioneers StePacPPC has customized its award-winning modified atmosphere packaging (MAP) films to preserve fresh whole and sliced white mushrooms, and whole exotic mushrooms, such as oyster, lion's mane, shiitake, portabella and more. The lean MAP system fulfills consumer demands for sustainable packaging that slows deterioration and dramatically reduces waste of this highly perishable item.

Key Points: 
  • The lean MAP system fulfills consumer demands for sustainable packaging that slows deterioration and dramatically reduces waste of this highly perishable item.
  • Growers and shippers are constantly grappling with these challenges, striving to improve mushroom storage capabilities and curb waste.
  • StePacPPC's latest advancement in its packaging formats is designed specifically to maintain the freshness of whole and sliced white mushrooms, and whole exotic mushrooms.
  • These lean and sustainable packaging formats can optionally be produced with 30% recycled material to support a circular economy.